Journal of Clinical Oncology, Vol 12, 1754-1763, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors

EK Rowinsky, DA Noe, DL Trump, EP Winer, VS Lucas, WA Wargin, JA Hohneker, B Lubejko, SE Sartorius and DS Ettinger
Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, Baltimore MD 21287-8934.

PURPOSE: The feasibility of administering vinorelbine (Navelbine, Burroughs Wellcome Co, Research Triangle Park, NC), a semisynthetic vinca alkaloid with broad activity, as a liquid-filled gelatin capsule was evaluated in a bioavailability (F) and pharmacokinetic study. PATIENTS AND METHODS: Each of 17 cancer patients had pharmacokinetic studies performed after receiving vinorelbine 30 mg/m2 intravenously (IV), which is the maximum-tolerated dose (MTD) for weekly IV administration, and twice after receiving the oral formulation at a nominal dose of 100 mg/m2. Subsequently, these patients and 10 other subjects received the oral formulation at a dose of 100 mg/m2/wk to evaluate the feasibility of chronic oral administration. RESULTS: Plasma drug disposition was well described by a triphasic model. Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow. F was low (0.27 +/- 12), and absorption was rapid (mean time of maximum plasma concentration [Tmax], 0.91 +/- 0.22 hours). Absorption parameters after the first and second oral doses were similar, with mean F values of 0.27 +/- 0.14 and 0.25 +/- 0.11, respectively. Coefficients of variability (CVs) for F, maximum plasma concentration (Cmax), and Tmax were 32%, 42%, and 78%, respectively, indicating moderate intraindividual variability. The pharmacologic profile of this oral formulation indicates that there is a large first-pass effect. Neutropenia was the principal toxicity of oral vinorelbine. Grade 3 or 4 neutropenia occurred in 63% of patients, but only 11% developed neutropenia and infection. Nausea, vomiting, and diarrhea were also common with oral administration, but these effects were rarely severe and could be ameliorated by using a divided-dose schedule and/or prophylactic antiemetic and antidiarrheal agents. The mean nominal oral dose was 82 mg/m2, and the mean percentage of intended dose that was received was 92%. Although dose escalations were permitted for negligible toxicity, doses were not escalated to greater than 100 mg/m2/wk in any patient. Vinorelbine given as a liquid-filled gelatin capsule at 100 mg/m2 provided equivalent pharmacologic exposure as 30 mg/m2 IV. CONCLUSION: The oral administration of vinorelbine, specifically as a liquid-filled, soft gelatin capsule, is a feasible route of administration. Weekly oral dosing at 100 mg/m2 induces a consistent degree of myelosuppression, but the high frequency of grade 3 or 4 neutropenia, albeit brief and uncomplicated, warrants the recommendation of a slightly lower starting dose, ie, 80 mg/m2/d, for subsequent phase II evaluations, especially in heavily pretreated patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Briasoulis, P. Pappas, C. Puozzo, C. Tolis, G. Fountzilas, U. Dafni, M. Marselos, and N. Pavlidis Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer Clin. Cancer Res., October 15, 2009; 15(20): 6454 - 6461. [Abstract] [Full Text] [PDF]

				M. Baweja, V. J. Suman, T. R. Fitch, J. A. Mailliard, A. Bernath, K. M. Rowland, S. R. Alberts, J. S. Kaur, and E. A. Perez Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients >=65 years of age: an NCCTG study Ann. Onc., April 1, 2006; 17(4): 623 - 629. [Abstract] [Full Text] [PDF]

				M. Johansen, J. Kuttesch, W. A. Bleyer, M. Krailo, M. Ames, and T. Madden Phase I Evaluation of Oral and Intravenous Vinorelbine in Pediatric Cancer Patients: A Report from the Children's Oncology Group Clin. Cancer Res., January 15, 2006; 12(2): 516 - 522. [Abstract] [Full Text] [PDF]

				G. Freyer, T. Delozier, M. Lichinister, D. Gedouin, P. Bougnoux, P. His, K. Imadalou, and V. Trillet-Lenoir Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy J. Clin. Oncol., January 1, 2003; 21(1): 35 - 40. [Abstract] [Full Text] [PDF]

				C. J. van Groeningen, G. J. Peters, J. H. Schornagel, H. Gall, P. Noordhuis, M. J. de Vries, S. L. Turner, M. S. Swart, H. M. Pinedo, A. R. Hanauske, et al. Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors J. Clin. Oncol., July 14, 2000; 18(14): 2772 - 2779. [Abstract] [Full Text] [PDF]

				A. Gauvin, F. Pinguet, S. Culine, C. Astre, R. Gomeni, and F. Bressolle Bayesian Estimate of Vinorelbine Pharmacokinetic Parameters in Elderly Patients with Advanced Metastatic Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2690 - 2695. [Abstract] [Full Text]

				G. I. Rodriguez, J. G. Kuhn, G. R. Weiss, S. G. Hilsenbeck, J. R. Eckardt, A. Thurman, D. A. Rinaldi, S. Hodges, D. D. Von Hoff, and E. K. Rowinsky A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea Blood, March 1, 1998; 91(5): 1533 - 1541. [Abstract] [Full Text] [PDF]